To: WhatsUpWithThat who wrote (16714 ) 12/26/2003 2:46:36 PM From: Bucky Katt Respond to of 48461 Maverick Scientist Is Winning Converts On Alzheimer's (BTW, not all melatonin is made from the pineal glands of mammals, there is also a synthetic version) Dr. Bush Was Widely Derided When He Said Zinc, Copper Played Role in Disease By BERNARD WYSOCKI JR. Staff Reporter of THE WALL STREET JOURNAL BOSTON -- Ashley Bush, a 44-year-old researcher at Harvard Medical School, was pilloried after he put forth a radical theory of Alzheimer's disease in 1994. "Worthless," wrote one scientific critic. Others have described his style as brash, his content as flimsy, and his ideas unworthy of being published. At worst, Dr. Bush recalled, it felt like "hate mail." Over the years, he submitted 30 scientific papers that were rejected by scientific journals. Eight times, his grant applications were spurned by the National Institutes of Health. Dr. Bush's theory is that the real culprit in Alzheimer's is a copper and zinc buildup in the brain -- an idea few scientists have looked at. He believes the accumulated metals mix abnormally with a protein called beta amyloid in the brain, oxidizing -- literally rusting -- and destroying nerve cells. Published in the prestigious journal Science, his hypothesis swiftly drew criticism because it ran counter to the leading theory that Alzheimer's disease is caused mainly by the protein clumps themselves. And by highlighting metals as the culprit, it drew scowls from some who thought it resembled a largely discredited theory that aluminum caused the disease. (He never saw aluminum as a culprit.) Now scientists are giving Dr. Bush more credence. He has a five-year grant from the NIH and this year won an American Academy of Neurology prize for Alzheimer's disease research. One big reason: He is on the trail of a drug that absorbs his culprits -- the excess copper and zinc -- and dissolves the protein clumps in the brains of experimental animals. Dr. Bush has found a potential Alzheimer's treatment in a 70-year-old dysentery drug with a history of toxic side effects. What's more, he and his colleagues this month published their first human clinical trial showing the drug's promise. "It's like Drano," he says. "It blows them away." More> online.wsj.com